
Korro Bio is a biotechnology company that develops and commercializes RNA editing therapies for the treatment of liver, eye and CNS disorders. Read more
Korro Bio is a biotechnology company that develops and commercializes RNA editing therapies for the treatment of liver, eye and CNS disorders. Read more
Korro Bio is a biotechnology company that develops and commercializes RNA editing therapies for the treatment of liver, eye and CNS disorders. Read more
CEO
Ram Aiyar
Founded:
2018
Status:
PrivateIndependent Company
ShapeTx is perceived as one of Korro Bio's biggest rivals. ShapeTx's headquarters is in Seattle, Washington, and was founded in 2018. ShapeTx operates in the Biotechnology industry. ShapeTx generates 55% of Korro Bio's revenue.
No recent acquisitions found related to Korro Bio
Since Korro Bio was founded in 2018, it has participated in 2 rounds of funding. In total Korro Bio has raised $95.5M. Korro Bio's last funding round was on Sep 2020 for a total of $91.5M
No recent investments found related to Korro Bio
400 Technology Square 10th Floor
Cambridge, Massachusetts02139
Driving Directions »